Zydus Cadila receives USFDA approval to market Vortioxetine Tablets

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

Sep 20, 2021 01:09 IST India Infoline News Service

Cadila Healthcare
Zydus Cadila, which is listed as Cadila Healthcare on stock exchanges, has bagged final approval from the USFDA to market Vortioxetine Tablets in the strengths of 5 mg, 10 mg, 20 mg (US RLD: Trintellix Tablets).

As per the regulatory filing, Vortioxetine is used to treat depression. It works by helping to restore the balance of a certain natural substance (serotonin) in the brain. Vortioxetine is an SSRI (selective serotonin reuptake inhibitor) and serotonin receptor modulator.

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 322 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

At around 1.46 pm, Cadila was trading at Rs556.05  per piece marginally down on Sensex. The stock has touched an intraday high and low of Rs559.95 per piece and Rs550.05 per piece respectively. 

Related Story

Open Free Demat Account (Rs699)